| Followers | 425 |
| Posts | 20207 |
| Boards Moderated | 1 |
| Alias Born | 02/22/2010 |
Friday, October 12, 2012 10:11:54 PM
INO Upcoming Catalysts
Multiple trial catalysts are set to unfold over the next couple of quarters, namely interim analysis of ongoing trials, but Wednesday's peer-reviewed validation comes as the story of the day for this stock and makes it one of this week's solid share price movers.
In addition to VGX-3100 Inovio has two other pipeline products in Phase II development and six others still in the earlier stages - all founded on the company's proprietary SynCon technology that produces synthetic vaccines to immunotherapeutically treat various infections diseases and cancer types.
Of note from the earlier-stage product, Inovio is working on bringing a universal flu shot to market that would potentially treat emerging strands of influenza, rather than just focusing on one strand, as is the standard for the treatments of today
Also on Wednesday it was reported that data from the earlier trial were published this week in the peer-reviewed journal "Science Transitional Medicine." Any time a developing biotech or small pharma rates a peer-review it is seen as a solid validation of a technology and/or trial results. Many investors do not solely take a company's word or spin of its own trials as a validation of results, but seek for such peer-reviewed confirmation as a routine part of their DD. Therefore, Wednesday's 15 percent price spike should be viewed as a solid vote of investor confidence, especially considering the markets were falling for the duration of the day.
http://stm.sciencemag.org/content/4/155/155ra138
http://stm.sciencemag.org/
Research Article HPV Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses Mark L. Bagarazzi,
Jian Yan,
Matthew P. Morrow,
Xuefei Shen,
R. Lamar Parker,
Jessica C. Lee,
Mary Giffear,
Panyupa Pankhong,
Amir S. Khan,
Kate E. Broderick,
Christine Knott,
Feng Lin,
Jean D. Boyer,
Ruxandra Draghia-Akli,
C. Jo White,
J. Joseph Kim,
David B. Weiner,
and Niranjan Y. Sardesai
Sci Transl Med 10 October 2012 4:155ra138. DOI:10.1126/scitranslmed.3004414
...an immune response in a phase 1 study. VGX-3100 is a candidate vaccine for the high-risk...cervical cancer-were given the DNA vaccine VGX-3100 by electroporation-where a small...show that the electroporation-delivered VGX-3100 induces a robust HPV-specific immune...
Multiple trial catalysts are set to unfold over the next couple of quarters, namely interim analysis of ongoing trials, but Wednesday's peer-reviewed validation comes as the story of the day for this stock and makes it one of this week's solid share price movers.
In addition to VGX-3100 Inovio has two other pipeline products in Phase II development and six others still in the earlier stages - all founded on the company's proprietary SynCon technology that produces synthetic vaccines to immunotherapeutically treat various infections diseases and cancer types.
Of note from the earlier-stage product, Inovio is working on bringing a universal flu shot to market that would potentially treat emerging strands of influenza, rather than just focusing on one strand, as is the standard for the treatments of today
Also on Wednesday it was reported that data from the earlier trial were published this week in the peer-reviewed journal "Science Transitional Medicine." Any time a developing biotech or small pharma rates a peer-review it is seen as a solid validation of a technology and/or trial results. Many investors do not solely take a company's word or spin of its own trials as a validation of results, but seek for such peer-reviewed confirmation as a routine part of their DD. Therefore, Wednesday's 15 percent price spike should be viewed as a solid vote of investor confidence, especially considering the markets were falling for the duration of the day.
http://stm.sciencemag.org/content/4/155/155ra138
http://stm.sciencemag.org/
Research Article HPV Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses Mark L. Bagarazzi,
Jian Yan,
Matthew P. Morrow,
Xuefei Shen,
R. Lamar Parker,
Jessica C. Lee,
Mary Giffear,
Panyupa Pankhong,
Amir S. Khan,
Kate E. Broderick,
Christine Knott,
Feng Lin,
Jean D. Boyer,
Ruxandra Draghia-Akli,
C. Jo White,
J. Joseph Kim,
David B. Weiner,
and Niranjan Y. Sardesai
Sci Transl Med 10 October 2012 4:155ra138. DOI:10.1126/scitranslmed.3004414
...an immune response in a phase 1 study. VGX-3100 is a candidate vaccine for the high-risk...cervical cancer-were given the DNA vaccine VGX-3100 by electroporation-where a small...show that the electroporation-delivered VGX-3100 induces a robust HPV-specific immune...
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
